Sanguine BioSciences, Inc.

The fate of a pharmaceutical drug or vaccine candidate is determined by the results of in vitro experiments in which the candidate’s effectiveness and safety are measured on human and animal cells and tissues. Therefore, researchers rely heavily on the quality and viability of these cells and tissues to deliver accurate results. However, many different cell types experience a sharp decrease in viability once they are isolated from human tissues. Sanguine BioSciences addresses this issue through proprietary cryopreservation protocols that increase the viability of these cells to >90%.

Sanguine BioSciences uses a dual-pronged platform to deliver its high viability cells and tissues. On the one hand, the company leverages its diverse network of blood banks, tissue collection sites, and raw materials providers to deliver its starting material (i.e. peripheral blood, cord blood, and hepatocytes [liver cells] from healthy and cancerous patients). Subsequently, the company processes & isolates the starting material into specific cells, and uses proprietary cryopreservation protocols enhance post-thaw viability (>90%).

As of October 2010, the company provides human tissues and cells derived from peripheral blood. Our peripheral blood product line includes whole blood, plasma, serum, platelets, red blood cells, peripheral blood mononuclear cells (PBMC) and its subpopulations; T cells, B cells, Natural Killer cells, and granulocytes including Basophils, Neutrophils, Eosinophils, and Dendritic cells.

Trojan Entrepreneur	Brian Neman
Company Name	Sanguine BioSciences, Inc.
Industry	Biotechnology
General Business Phone	1.888.765.5412
Email	brian@sanguinebio.com
Company Web Site	www.sanguinebio.com
Status	Revenue-Generating
School/Graduation Year	2008 for bachelors in biology, 2010 for masters in healthcare